Changeflow GovPing Pharma & Drug Safety Study Data Technical Conformance Guide Technica...
Routine Guidance Added Final

Study Data Technical Conformance Guide Technical Specifications Document

Favicon for www.fda.gov FDA Guidance Documents
Detected
Email

Summary

FDA issued technical specifications for study data conformance to guide sponsors and applicants on formatting study data submissions for drug and biologics regulatory review. The guidance applies to regulated product submissions under FDA jurisdiction. It represents current FDA thinking on technical data standards without creating new legal obligations.

Published by FDA on fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

FDA published technical specifications for study data conformance as guidance for regulated submissions. The document establishes technical standards for formatting and structuring study data submitted to the Center for Drug Evaluation and Research.\n\nPharmaceutical companies and sponsors submitting drug or biologics applications must ensure study data meets these technical specifications for regulatory review. The guidance is non-binding but represents FDA's current expectations for data submissions. Alternative approaches may be used if they satisfy applicable statutes and regulations.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Search for FDA
Guidance Documents

Docket Number: FDA-2014-D-0092 Issued by: Center for Drug Evaluation and Research This technical specifications document represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, send an email to cder-edata@fda.hhs.gov or cber.cdisc@fda.hhs.gov.

Submit Comments

Submit Comments Online You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-0092.

  • ## Content current as of:

04/16/2026

  • Regulated Product(s)

    • Biologics
    • Drugs

Get daily alerts for FDA Guidance Documents

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Substantive
Document ID
FDA-2014-D-0092
Docket
FDA-2014-D-0092

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug regulatory submissions Study data formatting
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Data Privacy Healthcare

Get alerts for this source

We'll email you when FDA Guidance Documents publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!